Tricida, Inc. (TCDA)

Market Cap	640.19M
Revenue (ttm)	n/a
Net Income (ttm)	-147.83M
Shares Out	55.67M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,122
Open	11.40
Previous Close	11.06
Day's Range	11.08 - 11.54
52-Week Range	4.10 - 13.85
Beta	0.53
Analysts	Buy
Price Target	19.72 (+71.5%)
Earnings Date	Nov 7, 2022

About TCDA

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

• Industry: Pharmaceuticals
• IPO Date: Jun 28, 2018
• CEO: Gerrit Klaerner
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: TCDA

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TCDA stock is "Buy." The 12-month stock price forecast is 19.72, which is an increase of 71.48% from the latest price.

Price Target

$19.72

(71.48% upside)

Analyst Consensus: Buy

Stock Forecasts